Global Meningococcal Vaccines Market - 2022-2029

Market Overview

Meningococcal Vaccines Market is expected to grow at a high CAGR of 12% during the forecasting period (2022-2029).

Meningococcal vaccines are designed to safeguard against Neisseria meningitidis infection. Vaccines available target certain meningococcus strains such as A, B, C, W-135, and Y. On average, the vaccines provide 80 percent to 100 percent immunity for two years, with some requiring booster doses. The vaccinations could be monovalent, targeting a specific kind of meningococcus, or multivalent.

Market Dynamics

The meningococcal vaccines market factors are the increase in demand for meningococcal vaccines and the increasing prevalence of meningitis.

The increase in demand for meningococcal vaccines is expected to drive market growth.

Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, like the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Meningococcus is the causative agent of meningitis, a severe disease characterized by fever, vomiting, and headache, similar to the common flu. The bacteria then travel through the body and grow rapidly, eventually reaching the blood, nerves, and brain. Developing a vaccine against meningococcus B is a watershed moment in modern medicine. Meningococcus B is a leading cause of disease in the Americas, Canada, Europe, Asia, and several other regions. On July 1, 2020, the meningococcal B vaccine (Bexsero) and the meningococcal ACWY vaccine (Nimenrix) were funded under the NIP beginning for people of all ages with certain medical conditions that increase their risk of IMD. Furthermore, on April 24, 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older. Hence, increasing demand for meningococcal vaccines is expected to boost the market growth.

The side effects associated with meningococcal vaccines are expected to hamper the market growth.

Approximately half of those who received a MenACWY vaccine experienced mild side effects, such as redness where the shot was administered, soreness in the area where the shot was administered, muscle aches, and headache. Four of the most common types of meningococcal bacteria are included in the menomune vaccine. Menomune commonly causes pain, redness, swelling, tenderness, or a lump at the injection site, usually lasting 1-2 days.

The CDC reports that roughly half of those who receive a meningococcal conjugate vaccine experience mild side effects, such as fever, redness, and pain where the shot was administered.

Industry Analysis

The meningococcal vaccines market provides in-depth analysis of the market based on various industry factors such as unmet needs, pricing analysis, supply chain analysis, regulatory analysis etc.

COVID-19 Impact Analysis

During the early stages of the pandemic, many countries suspended immunization programs to reduce the risk of spreading SARS-CoV-2. Many vaccination programs are halted due to COVID-19. Although vaccination programs did not cease in many other countries, vaccine uptake slowed due to containment measures (parents were uncertain about whether vaccinations were taking place and experienced difficulties booking appointments with widespread school closures). According to studies conducted in eight countries (the United States, the United Kingdom, Italy, France, Germany, Argentina, Brazil, and Australia), approximately half of parents delayed or canceled a scheduled meningococcal vaccination appointment for their child during the COVID-19 pandemic. The main reasons for this vaccination disruption are lockdown regulations (63%) and concerns about contracting SARS-CoV-2 (33%).

Segment Analysis

The conjugate vaccines segment is expected to hold the largest market share in the meningococcal vaccines market.

Meningococcal conjugate (MenACWY) vaccine protects against four types of Neisseria meningitidis bacteria (serogroups A, C, W, and Y). It is appropriate for all children and teenagers aged 11 and up. Some types of MenACWY are given to younger children (as young as 8 weeks) if they are at a higher risk of contracting meningococcal disease. Conjugate vaccine technology has been used successfully in childhood vaccines to prevent other bacterial meningitis pathogens, such as vaccines against Haemophilus influenzae serotype b (Hib) and, more recently, seven- and nine-valent conjugate pneumococcal vaccines. Meningococcal conjugate vaccines against N. meningitidis serogroup C are highly effective in young children and adolescents, with few side effects.

There are currently four quadrivalent meningococcal conjugate vaccine formulations available globally. All contain MenA, MenC, MenW, and MenY capsular polysaccharides, but the type of carrier protein varies. MenACWY-D (Menactra, Sanofi Pasteur) is conjugated to diphtheria toxoid (D), MenACWY-CRM (Menveo, GSK) is conjugated to CRM, and two MenACWY-TT vaccines, Nimenrix (Pfizer) and the recently available MenQuadfi are conjugated to TT (Sanofi Pasteur). Furthermore, On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

Geographical Analysis

North American region is expected to hold the largest market share in the global meningococcal vaccines market.

The rising prevalence of meningitis is expected to drive up demand for meningitis vaccines, resulting in rapid market growth. Various pathogens can cause meningitis, but bacterial meningitis has the highest global burden. According to the National Meningitis Association (NMA), approximately 600-1,000 people in the United States contract meningococcal disease each year. Furthermore, preteens, teens, and young adults account for 21% of meningococcal disease cases.

Furthermore, the growing public awareness of the disease is expected to drive market growth in this region. The Meningitis Foundation of America (MFA) is a non-profit organization in the United States dedicated to providing information and support to people with personal experiences with meningitis. This foundation also aims to raise public and medical awareness about the early symptoms of meningitis. As a result, the meningococcal vaccine market is expected to grow steadily over the forecast period.

Competitive Landscape

Major key players in the meningococcal vaccines market are Bio-Manguinhos, Biomed Pvt. Ltd, GlaxoSmithKline PLC, Merck & Co., Inc., Pfizer Inc., Sanofi Pasteur Inc., Serum Institute of India Ltd., Walvax Biotechnology Co., Ltd, Incepta Pharmaceuticals Ltd., Chongqing Zhifei Biological Products Co., Ltd.

Sanofi Pasteur Inc.:

Overview:

Sanofi Pasteur is the world's largest company solely dedicated to vaccines. The vaccines division of the French multinational pharmaceutical company Sanofi is known as Sanofi Pasteur. The company's business is divided into pharmaceuticals, chemicals, vaccines, and consumer healthcare.

Product Portfolio:

MenQuadfi is a vaccine given to people aged 2 to help prevent invasive meningococcal disease (including meningitis) caused by the bacterium N meningitides serogroups A, C, W, and Y. Serogroup B disease is not prevented by MenQuadfi.

Key Developments:

On 24 April 2020, the FDA approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine to prevent invasive meningococcal disease in people aged 2 years and older.

The global meningococcal vaccines market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.